Network-1 Technologies Says Effective Dec. 21, 2022 Board Elected Robert Mahan As Co.’s New Chief Financial Officer

-SEC Filing

-SEC Filing

Total
0
Shares
Related Posts
Read More

Unicycive Issued Notice Of Acceptance To Initiate Phase 1 Study Of UNI-494 Following Review Of Clinical Trial Application By The Medicines And Healthcare Products Regulatory Agency In The United Kingdom

Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, announced today that the Medicines and Healthcare Products Regulatory Agency

UNCY